Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2022-07-25 / Epigenomics 2022 Jul;14(14):865-886An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2022-07-15 / Clin Cancer Res 2022 Jul;28(14):3053-3065Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2022-01-01 / J Immunother Cancer 2022 Jan;10(1)Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2021-07-20 / Gynecol Oncol 2021 Sep;162(3):652-660Modulated electro-hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial
/in Hyperthermia, International Publications, Ovarian Cancer /von 2021-05-21 / Exp Ther Med 2021 Jul;22(1):787Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-10-14 / Nat Commun 2020 10;11(1):5173Advanced clinical trials of dendritic cell vaccines in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-07-27 / J. Investig. Med. 2020 Jul;Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-07-13 / Immunol. Invest. 2020 Jul;:1-18Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-04-22 / Curr. Opin. Biotechnol. 2020 Apr;65:190-196
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de